Navelbine (Vinorelbine)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral dosage form for oral use. It treats non‑small cell lung cancer and metastatic breast cancer in adult patients.

GNH USA supplies Navelbine as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine is employed in the management of solid tumours that are responsive to antimitotic chemotherapy. - Non‑small cell lung cancer: used in first‑line or subsequent therapy to control tumor growth in adult patients. - Metastatic breast cancer: employed to reduce tumor burden and alleviate symptoms in advanced disease. - Relapsed or refractory solid tumours: may be considered when other chemotherapy options have failed, under specialist supervision.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Neutropenia: reduced white blood cell count. - Anemia: lowered red blood cell levels. - Constipation: decreased bowel movements. - Alopecia: hair thinning or loss. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe neutropenia with infection risk: may lead to febrile episodes. - Febrile neutropenia: fever accompanying low neutrophils. - Peripheral neuropathy: tingling or numbness in extremities. - Pulmonary toxicity: cough, dyspnea, or interstitial lung changes. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm observed in rare cases.

Before initiating therapy, clinicians should assess patient-specific factors and monitor for toxicity. - Dose adjustment in renal impairment: reduce dose according to renal function. - Monitor blood counts regularly: watch for neutropenia and anemia. - Assess hepatic function before therapy: dose may need modification. - Avoid in patients with known hypersensitivity to vinorelbine or other vinca alkaloids. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Vinorelbine can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole): may increase vinorelbine exposure. - Co‑administration with other myelosuppressive agents: heightened risk of severe bone‑marrow suppression. - Combination with CYP3A4 inducers (e.g., rifampicin): may reduce efficacy.

Moderate Interactions (Monitor Closely): - Concurrent use with anti‑emetics that affect QT interval: monitor cardiac rhythm. - Use with warfarin: monitor INR for possible changes. - Combination with radiotherapy: increased risk of pulmonary toxicity.